Retrospective analysis of transarterial radioembolization (TARE) in hormone-secreting neuroendocrine tumors (NET) at University Hospital Essen

Retrospective analysis of transarterial radioembolization (TARE) in hormone-secreting neuroendocrine tumors (NET) at University Hospital Essen - TARE HA NET

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037892

Enrollment

Registered

2025-09-12

Start date

2025-10-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Histologically confirmed hormone-secreting neuroendocrine tumor (NET) (C7B.02 — Secondary neuroendocrine tumor of liver)

Interventions

Group 1: Retrospective Analysis of Transarterial Radioembolization (TARE) in Hormone-Secreting Neuroendocrine Tumors (NETs) at the University Hospital Essen Data Sources Imaging datasets (CT, MRI, SP

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histologically confirmed hormone-secreting neuroendocrine tumor (NET) TARE performed during the specified period at University Hospital Essen Complete documentation of treatment and follow-up data

Exclusion criteria

Exclusion criteria: Incomplete documentation

Design outcomes

Primary

Measure	Time frame
Overall survival (OS) from TARE Progression-free survival (PFS) in the liver	—

Secondary

Measure	Time frame
Radiological response (mRECIST / RECIST 1.1) Adverse event profile (CTCAE v5.0) Changes in hormonal parameters (e.g., serotonin, chromogranin A) and symptom control Need for further locoregional or systemic therapies	—

Countries

Germany

Contacts

Public ContactThomas Dertnig

Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie

Thomas.Dertnig@uk-essen.de+4917641134629

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026